# Risk Assessment: SAN.PA (Sanofi)

## Fecha: 2026-02-09

## Risk Score: HIGH

---

## Matriz de Riesgos

| # | Categoria | Riesgo | Probabilidad | Impacto | Score | Mitigante |
|---|-----------|--------|-------------|---------|-------|-----------|
| 1 | Fundamental | Dupixent successor pipeline failure (amlitelimab, itepekimab) | Alta | Alto | CRITICAL | None adequate; bolt-on M&A is plan B |
| 2 | Legal | Dupixent CTCL mass tort litigation | Media | Alto | HIGH | Early stage; causal link debated |
| 3 | Financial | ROIC spread NEGATIVE; goodwill EUR 40B masks capital destruction | Alta | Medio | HIGH | FCF strong at EUR 8.1B |
| 4 | Fundamental | Dupixent patent cliff 2031 concentration (36% revenue) | Media | Alto | HIGH | 5-year runway; new indications |
| 5 | Legal | Regeneron partnership lawsuit (PBM transparency) | Media | Medio | MEDIUM | Commercial dispute, not product |
| 6 | Legal/Tax | French tax fraud investigation (SocGen scheme) | Media | Medio | MEDIUM | "Complied with all laws" defense |
| 7 | Regulatory | IRA Medicare drug price negotiation (Dupixent eligible 2031+) | Media | Medio | MEDIUM | Biologics 11-year exclusivity delay |
| 8 | Macro | Trump pharma tariffs on EU exports to US | Media | Medio | MEDIUM | Exemptions via pricing deals |
| 9 | Valoracion | Quality Score discrepancy: thesis 9/10 vs tool 59/100 | Alta | Medio | HIGH | Systematic tool is more reliable |
| 10 | Fundamental | Opella post-divestiture drag (EUR 622M loss since May 2025) | Baja | Medio | LOW | Retained 48.2% stake; one-time |
| 11 | Legal | $15B Oregon whistleblower lawsuit + IRS involvement | Baja | Alto | MEDIUM | Unverified; SEC omission concerning |
| 12 | Fundamental | Dupixent safety signal - FDA FAERS review | Media | Alto | HIGH | Under FDA evaluation; no action yet |
| 13 | Governance | CEO succession / French government interference | Baja | Medio | LOW | Hudson stable; Opella deal closed |
| 14 | Macro | EUR/USD currency impact (-2% sales, -3% EPS per guidance) | Media | Bajo | LOW | Natural hedging; structural |

### Scoring Key:
- Alta x Alto = CRITICAL
- Alta x Medio OR Media x Alto = HIGH
- Media x Medio = MEDIUM
- Baja x cualquiera OR cualquiera x Bajo = LOW

---

## Top 3 Riesgos Criticos

### 1. Dupixent Successor Pipeline Failure -- THE STRATEGIC RISK

- **Categoria:** Fundamental
- **Descripcion:** Sanofi's entire post-2031 strategy depends on developing Dupixent successors and diversifying the pipeline. In 2025, THREE key programs failed or disappointed:
  - **Amlitelimab** (anti-OX40L): Phase III met endpoints but efficacy was "well below expectations" -- EASI-75 of 17-20% placebo-adjusted vs Dupixent's 32-34%. Stock fell 10% on the data. This was positioned as the Dupixent successor in atopic dermatitis.
  - **Itepekimab** (anti-IL-33): Failed Phase III in COPD entirely. This was expected to broaden Dupixent's immunology franchise into respiratory.
  - **Tolebrutinib** (BTK inhibitor): Missed primary endpoint in progressive MS (PERSEUS trial). FDA also delayed approval for non-relapsing SPMS due to liver toxicity concerns.
  - **Balinatunfib** (oral TNF): Missed Phase 2 psoriasis endpoint.
- **Evidencia:** UBS downgraded Sanofi to Neutral specifically citing "failure to address pipeline replacement power is too great a strategic risk." UBS stated "meaningful M&A may be the only realistic solution." Guggenheim and Barclays also downgraded.
- **Probabilidad:** Alta (70%) -- The failures have ALREADY happened. The question is whether remaining pipeline (25+ P3 readouts in 2026) can compensate. History says ~80% of pipeline drugs fail.
- **Impacto si materializa:** Severe. If no successor emerges by 2029-2030, Dupixent's EUR 14B+ revenue (growing to EUR 22B target) faces biosimilar erosion of 40-60% within 3 years post-patent. At 36% of total revenue, that is a 14-22% revenue decline scenario. Fair value impact: -25% to -35%.
- **Mitigante:** 25+ P3 readouts in 2026 provide multiple shots on goal. ALTUVIIIO already >$1B. Dynavax acquisition adds vaccine platform. EUR 8.1B FCF enables bolt-on M&A.
- **Kill condition?:** YES -- If 2026 pipeline readouts continue to disappoint (>60% failure rate in material programs), the thesis is fundamentally weakened. Already at Kill Trigger #5 in thesis: "Pipeline failure rate >60% in 2026."

### 2. Dupixent CTCL/T-Cell Lymphoma Safety Signal -- THE EMERGING MASS TORT

- **Categoria:** Legal / Regulatory
- **Descripcion:** The FDA placed Dupixent on its FAERS "Potential Signals" list in March 2025 for cutaneous T-cell lymphoma (CTCL). Key facts:
  - 300+ adverse event reports involving lymphoma diagnoses filed with FDA
  - Published research shows 4x increase in CTCL diagnoses among Dupixent users (Journal of American Academy of Dermatology)
  - CTCL reporting rate is 30x higher for Dupixent vs all other medications
  - First wrongful death lawsuit filed October 2025 (Tennessee)
  - CTCL mimics eczema visually, meaning Dupixent may have MASKED cancer diagnoses in patients being treated for atopic dermatitis
  - FDA evaluating "need for regulatory action" -- could result in black box warning
  - Multiple law firms actively recruiting plaintiffs (emerging mass tort)
  - 5,335 adverse event reports in FDA FAERS database
- **Evidencia:** FDA FAERS listing is objective. Published research in peer-reviewed journals. First lawsuit filed. Multiple law firms on record. This follows the classic mass tort escalation pattern (Roundup, Zantac, opioids).
- **Probabilidad:** Media (40-50%) that this escalates to material litigation. The science is still debated. But the pattern is concerning: FDA signal -> lawsuits -> MDL -> massive settlement.
- **Impacto si materializa:**
  - **Scenario A (Black box warning only):** Reduced new patient starts, -10-15% Dupixent revenue growth trajectory. FV impact: -10%.
  - **Scenario B (Full mass tort, thousands of cases):** Settlement could be $2-5B+ (Roundup comparison: $11B for Bayer). Shared 50/50 with Regeneron. FV impact: -5-10% from settlement + revenue impact.
  - **Scenario C (Worst case: withdrawal):** Kill condition. -36% revenue. Devastating.
  - Most likely: Label change + some litigation. FV impact: -5-10%.
- **Mitigante:** CTCL is rare (~7 per million). Correlation vs causation debate ongoing. Dupixent has treated millions safely. Shared liability with Regeneron. But the thesis DOES NOT mention this risk at all.
- **Kill condition?:** YES -- This should be added as Kill Trigger #1a: "Dupixent FDA-mandated withdrawal or black box warning for cancer risk."

### 3. ROIC Spread Negative + Goodwill-Inflated Balance Sheet -- THE HIDDEN QUALITY PROBLEM

- **Categoria:** Financial / Valoracion
- **Descripcion:** The thesis claims "ROIC ~10-12% vs WACC 8% = economic moat confirmed" and assigns Quality Score 9/10 (Tier A). But the systematic quality_scorer.py gives 59/100 (Tier B) with ROIC spread NEGATIVE at -2.1 percentage points. This is a fundamental contradiction.
  - **Why ROIC is negative:** Sanofi has EUR 40.3B in goodwill (as of June 2025) from decades of acquisitions (Genzyme $20B, Aventis, etc.). When goodwill is included in invested capital (as it should be for assessing capital allocation), ROIC drops to ~6-8% -- below the 8% WACC.
  - **Historical ROIC (GuruFocus):** Averaged 8.1% over 5 years (2021-2025), median 8.0%. This is AT or BELOW WACC, not above it.
  - **The thesis's "10-12% ROIC" likely excludes goodwill**, which paints a false picture of value creation. If you exclude goodwill from invested capital, you are ignoring the price paid for acquisitions -- the very capital that was invested.
  - **Goodwill = 41% of total assets** (EUR 40.3B / ~EUR 98B). This is massive. While no impairment has been taken, the goodwill represents overpayment for past acquisitions that has never been written down. If pipeline programs continue to fail, goodwill impairment becomes a real risk.
  - **Intangible asset impairments already happening:** EUR 210M in H1 2025 for R&D projects. Marketed products carried at EUR 11.0B declining from EUR 12.7B.
- **Evidencia:**
  - quality_scorer.py: Financial Quality 19/40, ROIC spread -2.1pp
  - GuruFocus: 5-year average ROIC 8.1% (barely at WACC)
  - Goodwill EUR 40.3B (H1 2025)
  - R&D impairments EUR 210M (H1 2025)
- **Probabilidad:** Alta (80%) -- This is not a future risk, it is a CURRENT REALITY. ROIC has been at/below WACC for years. The thesis misrepresents this.
- **Impacto si materializa:** The thesis's Quality Score is wrong. Sanofi is NOT a Tier A quality compounder (QS 75+). At QS 59 (Tier B), the required MoS should be higher. The thesis's EUR 122 base fair value assumes a quality premium that does not exist.
  - If we adjust from Tier A expectations to Tier B, the appropriate valuation discount is 10-15%.
  - Goodwill impairment of even 10% (EUR 4B) would reduce book value meaningfully, though this is more of an accounting risk than a cash flow risk.
  - The real impact: this is not a "wide moat" business that compounds capital. It is a business that barely earns its cost of capital AFTER accounting for acquisition costs. The intrinsic value ceiling is lower.
- **Mitigante:** FCF of EUR 8.1B is REAL cash, regardless of ROIC accounting. Dividends are well-covered by FCF. The business generates cash even if ROIC is mediocre. But this is a "cash cow" profile, not a "quality compounder" profile.
- **Kill condition?:** NO, but it should CHANGE the thesis classification from Tier A to Tier B, and reduce the fair value estimate by incorporating a quality discount.

---

## Riesgos NO Mencionados en Thesis

| Riesgo | Severidad | Mencionado en thesis? | Comentario |
|--------|-----------|----------------------|------------|
| Dupixent CTCL mass tort / FDA safety review | HIGH | NO | Thesis does not mention CTCL, FDA FAERS signal, or any product liability risk for Dupixent. This is a MATERIAL omission given 300+ adverse events and active FDA evaluation. |
| Pipeline failures (amlitelimab, itepekimab, tolebrutinib) | HIGH | Minimizado | Thesis says "25+ P3 readouts" but does not mention that three KEY programs already failed/disappointed in 2025. This changes the narrative from "diversified pipeline" to "pipeline in crisis." |
| Regeneron partnership lawsuit | MEDIUM | NO | Thesis does not mention that Regeneron has SUED Sanofi over lack of transparency in Dupixent PBM agreements. This creates risk to the most important commercial partnership. |
| French tax fraud investigation (HQ raided) | MEDIUM | NO | Sanofi HQ was raided by 30 ONAF inspectors. Investigation involves SocGen financing scheme. Thesis silent on this. |
| ROIC spread is NEGATIVE (not positive as thesis claims) | HIGH | Misrepresented | Thesis claims "ROIC 10-12% vs WACC 8%" but systematic tool shows ROIC spread of -2.1pp. This is a FACTUAL ERROR in the thesis. |
| Quality Score is 59 Tier B (not 9/10 Tier A as thesis claims) | HIGH | Misrepresented | Thesis uses ad-hoc "9/10" scoring. Systematic tool gives 59/100 = Tier B. This discrepancy should have been a RED FLAG. |
| $15B Oregon whistleblower lawsuit + SEC disclosure concerns | MEDIUM | NO | Unclear materiality but the SEC disclosure omission is concerning. |
| Opella EUR 622M net loss post-divestiture | LOW | NO | Sanofi retains 48.2% equity stake. Losses flow through associates. |
| Zantac ongoing litigation (20,000 claims in Delaware) | LOW-MEDIUM | NO | Sanofi settled 4,000 claims for $100M but 20,000 remain in Delaware. |
| Trump pharma tariffs on EU (15-25% proposed) | MEDIUM | Minimizado | Thesis says "not directly affected" but EU pharma exports to US are EUR 84.4B; Sanofi has significant US revenue exposed. |
| Analyst downgrades (UBS, Guggenheim, Barclays) | MEDIUM | NO | Multiple downgrades specifically citing pipeline weakness. Consensus target EUR 99 vs thesis EUR 122. |

---

## Kill Conditions Sugeridas

Based on my findings, the following kill conditions should be ADDED to the thesis:

1. **Dupixent FDA black box warning or withdrawal for CTCL/cancer risk** -- This is an existential risk to the drug that generates 36% of revenue. The thesis lists "Dupixent safety signal" as Kill Trigger #1 but does not specifically mention the ACTIVE FDA evaluation of CTCL. This should be made explicit.

2. **Regeneron terminates or fundamentally alters Dupixent collaboration** -- The partnership lawsuit raises the possibility of a fractured relationship. While unlikely to result in termination, it introduces uncertainty about the commercial future of the company's most important product.

3. **Goodwill impairment >EUR 5B** -- With EUR 40.3B in goodwill and pipeline programs failing, a large impairment would signal that management acknowledges past acquisition value destruction. This would crater the stock and confirm the ROIC problem.

4. **2026 pipeline failure rate exceeds 60% in material programs** -- Already at the threshold. If the remaining 2026 readouts disappoint at this rate, there is no credible post-Dupixent story.

5. **Mass tort MDL formation for Dupixent CTCL with >5,000 plaintiffs** -- If this crosses from "emerging" to "established" mass tort, the financial and reputational impact could be severe.

---

## Riesgo Agregado

- **Numero de riesgos HIGH+CRITICAL:** 5 (pipeline failure CRITICAL, CTCL HIGH, ROIC/quality HIGH, patent cliff HIGH, FDA safety signal HIGH)
- **Riesgos correlacionados?** YES -- Risks #1, #2, #4, and #12 are ALL correlated through Dupixent. If Dupixent faces safety issues (#2, #12), the patent cliff (#4) becomes MORE dangerous because the successor pipeline has already failed (#1). This is a concentrated, correlated risk cluster around a single product.
- **Risk Score Final: HIGH**

### Justification for HIGH (not VERY HIGH):
Despite having one CRITICAL and four HIGH risks, the company has genuine mitigants: EUR 8.1B FCF, strong dividend coverage, investment grade balance sheet, diversified revenue beyond Dupixent (vaccines, rare disease = ~64% of revenue), and 5+ years before patent cliff materializes. The VERY HIGH rating would apply if the CTCL mass tort escalated to MDL status or if 2026 pipeline readouts continued the failure pattern.

---

## Valuation Risk Assessment

### Thesis Fair Value vs My Assessment

| Metric | Thesis Claim | My Assessment | Gap |
|--------|-------------|---------------|-----|
| Quality Score | 9/10 Tier A | 59/100 Tier B | Thesis overrates by ~2 tiers |
| ROIC vs WACC | 10-12% vs 8% (positive) | ~6-8% vs 8% (negative/neutral) | Thesis WRONG on sign |
| Base Fair Value | EUR 122 | EUR 90-100 | -18% to -26% |
| Bear Fair Value | EUR 98 | EUR 75-85 | -13% to -23% |
| Analyst consensus target | N/A in thesis | EUR 99 (average of 23 analysts) | Aligned with my range |

### Why I think EUR 122 is too high:
1. **DDM at 60% weight is aggressive.** Using DDM as primary method for a company whose ROIC barely covers WACC is questionable. DDM works best for true compounders, not capital-intensive pharma with goodwill-laden balance sheets.
2. **Dividend growth of 4% assumes earnings growth.** But if pipeline fails and Dupixent erodes, EPS could DECLINE post-2031. Payout ratio is already 97% -- there is ZERO margin for dividend growth if earnings stagnate.
3. **DCF growth assumptions (6% Y1-5) are reasonable** but ignore that 2025 had abnormally high growth (+15% business EPS) driven by Dupixent expansion into new indications and Opella deconsolidation effects.
4. **No quality discount applied.** A Tier B company (QS 59) should trade at a lower multiple than a Tier A. The thesis applies Tier A valuation to Tier B quality.
5. **Analyst consensus of EUR 99** is 19% below thesis base case. When your thesis is 19% above sell-side consensus (which is already biased bullish), that is a signal.

### My Fair Value Range:
- **Bear (pipeline fails, CTCL escalates):** EUR 70-80
- **Base (status quo, pipeline mixed):** EUR 90-100
- **Bull (pipeline succeeds, no safety issues):** EUR 115-125
- **Probability-weighted:** EUR 92-100

At current price of EUR 80.36, the MoS vs my base case is 12-20%, not 34% as thesis claims. This is Tier B territory requiring 20-25% MoS per precedents, meaning the position is marginally acceptable at best.

---

## ðŸ”„ META-REFLECTION

### Dudas/Incertidumbres
- The $15B Oregon whistleblower lawsuit is difficult to verify through mainstream sources. The claim comes from a dedicated website (15billiondollarcase.com) which could be exaggerated litigation marketing. I could not confirm the $15B figure through SEC filings or major financial news outlets. I classify this as LOW probability but flag it because the SEC disclosure omission allegation is independently concerning.
- The CTCL mass tort is genuinely early-stage. It could fizzle (like many emerging mass torts) or explode (like Roundup). I cannot assign a confident probability. I used 40-50% for "material escalation" which is a wide range.
- Sanofi's FY2025 results were genuinely strong (9.9% revenue growth, 15% business EPS growth, EUR 8.1B FCF). This makes it tempting to dismiss risks. But strong current results are exactly what big pharma looks like BEFORE a patent cliff -- the peak is the most dangerous moment.

### Riesgos que Podrian Estar Subestimados
- **Dupixent CTCL mass tort:** I rated this as HIGH but it could be CRITICAL if an MDL forms and thousands of cases emerge. The Roundup comparison (Bayer paid $11B+) is not far-fetched if CTCL causation is established. This is the single risk I am least confident about sizing.
- **Trump pharma tariffs:** I rated this MEDIUM but the EU pharma industry has EUR 84.4B in US exports. If tariffs hit 25%, the margin impact across the sector would be severe. Sanofi generates ~40% of revenue in the US.
- **Regeneron lawsuit:** Rated MEDIUM, but if this fractures the partnership, the commercial disruption to Dupixent (their $14B product) could be HIGH.

### Discrepancias con Thesis
The discrepancies are severe and systematic:
1. **Quality Score:** Thesis says 9/10 Tier A. Tool says 59/100 Tier B. This is not a minor difference -- it is a two-tier gap that changes the entire investment framework.
2. **ROIC:** Thesis says positive spread (10-12% vs 8% WACC). Data says negative spread (-2.1pp). This is a FACTUAL ERROR, not a difference of opinion.
3. **Pipeline narrative:** Thesis says "25+ P3 readouts = diversified pipeline." Reality: three key successor programs failed in 2025 (amlitelimab, itepekimab, tolebrutinib). The "diversified pipeline" narrative is weakened.
4. **Risk identification:** Thesis identifies 5 risks, all rated MEDIUM or lower. I found 14 risks, including 5 HIGH and 1 CRITICAL. The thesis is systematically underestimating risk.
5. **Fair value:** Thesis says EUR 122 base. Analyst consensus says EUR 99. My assessment says EUR 90-100. The thesis appears to be an outlier on the bullish side.
6. **CTCL omission:** The thesis does not mention the FDA safety investigation or emerging mass tort for Dupixent's most important product. This is a material omission.

### Sugerencias para el Sistema
1. **Mandatory quality_scorer.py cross-check:** The thesis used an ad-hoc 9/10 quality score that contradicted the systematic tool (59/100). The system should REQUIRE that any thesis quality claim be validated against the tool, with explicit reconciliation if they diverge.
2. **Product liability search should be mandatory for pharma positions:** Dupixent CTCL risk was findable via basic WebSearch. The fundamental-analyst should have searched for "[drug name] lawsuit" and "[drug name] safety concern" for every material drug.
3. **ROIC calculation should specify goodwill treatment:** The thesis claimed ROIC 10-12% without specifying whether goodwill was included. This ambiguity allowed a misleading claim. Future pharma theses should state ROIC with and without goodwill.
4. **Analyst consensus should be compared against thesis FV:** A 19% gap between thesis FV and consensus should trigger automatic review. While consensus can be wrong, a large gap means either the thesis has superior insight or it has an error.

### Preguntas para Orchestrator
1. Given the QS discrepancy (thesis 9/10 vs tool 59/100) and the ROIC error (thesis claims positive spread, data shows negative), should this thesis be sent back for complete rewrite rather than just updating risk factors?
2. The Dupixent CTCL mass tort is an emerging risk that the thesis does not mention. Should this be elevated to a kill condition immediately, or should we wait for the FDA to complete its evaluation?
3. At EUR 80.36, with my adjusted FV of EUR 90-100, the MoS is only 12-20%. For Tier B quality, precedents suggest 20-25% MoS is needed. Does the current position justify HOLD or should we consider TRIM/EXIT given the unfavorable risk-adjusted picture?
4. Multiple analysts (UBS, Guggenheim, Barclays) have downgraded specifically citing pipeline weakness. The thesis dismisses this. Should the orchestrator treat analyst downgrades as confirming evidence for the pipeline risk rather than ignoring them?

---

## Sources

### Dupixent Patent & Biosimilar Timeline
- [DrugPatentWatch: Dupixent Patents](https://www.drugpatentwatch.com/p/biologics/tradename/DUPIXENT)
- [MedXDRG: Dupixent Exclusivity & Expiry](https://medxdrg.com/how-long-is-the-patent-on-dupixent-an-analysis-of-market-exclusivity-and-biosimilars)
- [Formycon FYB208 Dupilumab Biosimilar](https://www.drugpatentwatch.com/p/biologics/ingredient/dupilumab)

### Pipeline Setbacks
- [UBS Cuts Sanofi to Neutral Amid Pipeline Setbacks](https://stockinvest.us/digest/ubs-cuts-sanofi-to-neutral-amid-pipeline-setbacks-and-dupixent-patent-concerns)
- [Sanofi Trims R&D Priorities](https://european-biotechnology.com/latest-news/sanofi-ends-2025-on-a-high-but-trims-rd-priorities/)
- [BioSpace: Amlitelimab Falls Below Expectations](https://www.biospace.com/drug-development/sanofis-anti-ox40-blocker-falls-well-below-expectations-in-phase-iii-eczema-study)
- [Itepekimab COPD Phase III Failure](https://www.biospace.com/drug-development/sanofi-regeneron-shares-tumble-as-dupixent-follow-up-fails-phase-iii-copd-test)
- [Tolebrutinib MS Trial Failure](https://www.fiercebiotech.com/biotech/sanofi-corcept-surprised-fda-rejections-ms-cushings-syndrome-drugs)

### CTCL Safety Signal & Mass Tort
- [FDA Evaluating Dupixent CTCL Warning](https://www.aboutlawsuits.com/dupixent-lawsuit/fda-investigating-dupixent-cutaneous-t-cell-lymphoma-regulatory-action/)
- [Dupixent Lawsuits January 2026 Update](https://levinlaw.com/dupixent-lawsuits/)
- [Consumer Notice: Dupixent CTCL Risk](https://www.consumernotice.org/news/dupixent-use-linked-to-higher-risk-of-rare-skin-lymphoma-studies-show/)

### Litigation & Investigations
- [Regeneron Sues Sanofi Over Dupixent Pact](https://www.biospace.com/business/regeneron-sues-sanofi-alleging-stonewalling-in-dupixent-pact)
- [Sanofi HQ Raided in Tax Fraud Probe](https://pharmaphorum.com/news/sanofis-paris-hq-raided-tax-fraud-probe)
- [$15B Whistleblower Case](https://www.15billiondollarcase.com/)
- [Sanofi Zantac Settlement $100M](https://www.fiercepharma.com/pharma/sanofis-zantac-settlement-was-100m-or-25k-claimant-bloomberg-report)

### Analyst Downgrades
- [UBS Downgrades Sanofi to Neutral](https://www.investing.com/news/analyst-ratings/ubs-downgrades-sanofi-stock-rating-to-neutral-on-pipeline-concerns-93CH-4451073)
- [Sanofi Analyst Consensus](https://stockanalysis.com/stocks/sny/ratings/)
- [TipRanks: Sanofi Forecast](https://www.tipranks.com/stocks/sny/forecast)

### Financial Data
- [Sanofi FY2025 Results Press Release](https://www.sanofi.com/en/media-room/press-releases/2026/2026-01-29-06-30-00-3228191)
- [Sanofi Half-Year Financial Report 2025](https://www.sanofi.com/assets/dotcom/content-app/publications/half-year-financial-reports/Half-year-financial-report-2025.pdf)
- [GuruFocus: Sanofi ROIC](https://www.gurufocus.com/term/ROIC/SNY/Return+on+Invested+Capital/Sanofi/)

### Macro & Tariffs
- [Trump Pharma Tariffs EU Impact](https://www.fiercepharma.com/pharma/trump-tariffs-drugs-industry-warns-eu-100b-plus-pharma-exodus-us)
- [EU Pharma Export Data](https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius)

### Opella Divestiture
- [Sanofi & CD&R Close Opella Transaction](https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-30-11-00-00-3071167)

### IRA Drug Pricing
- [KFF: IRA Drug Price Negotiation FAQs](https://www.kff.org/medicare/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program/)
- [CMS: Medicare Drug Price Negotiation Program](https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation)
